Meeting
2023 ASCO Genitourinary Cancers Symposium
Assessing treatment preferences among patients with advanced/metastatic renal cell carcinoma in the United States: A discrete choice experiment.
Authors
Moshe Chaim Ornstein
Cleveland Clinic, Cleveland, OH
Moshe Chaim Ornstein , Lisa Rosenblatt , Flavia Ejzykowicz , Sarah Guttenplan , Viviana Del Tejo , Xin Yin , Kathleen M. Beusterien , deMauri S Mackie , Oliver Will , Grace Skiles , Marc DeCongelio , Steven S. Senglaub
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 630)
DOI
10.1200/JCO.2023.41.6_suppl.630
Abstract #
630
Poster Bd #
E20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer.
First Author: Smadar Bauer
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient and physician preferences for adjuvant treatment of renal cell carcinoma: A discrete-choice experiment.
First Author: Shawna R Calhoun
Poster
2023 ASCO Genitourinary Cancers Symposium
Heterogeneity in physician and patient preferences for the treatment of renal cell carcinoma: Evidence from latent class analysis.
First Author: Caroline Vass
Poster
2022 ASCO Annual Meeting
A randomized phase II study of anlotinib combined with STUPP versus STUPP alone in patients with newly diagnosed glioblastoma (GBM).
First Author: Yuan yuan Yuan Chen